Industry Data Request

Similar documents
Table 1: CD4 category by treatment regimens (reproduction of ASR report table specifically CD4 re categorisation of CD4) (a) (b) 2009.

Industry Request Integrase Inhibitors

THE HIV LIFE CYCLE. Understanding How Antiretroviral Medications Work

HIV MEDICATIONS AT A GLANCE. Atripla 600/200/300 mg tablet tablet daily. Complera 200/25/300 mg tablet tablet daily

Risk of HIV-1 low level viremia to treatment. Germany. Nadine Lübke Düsseldorf

Central Nervous System Penetration of ARVs: Does it Matter?

Antiretroviral Dosing in Renal Impairment

0.14 ( 0.053%) UNAIDS 10% (94) ( ) (73-94/6 ) 8,920

HIV Drugs and the HIV Lifecycle

WOMENS INTERAGENCY HIV STUDY ANTIRETROVIRAL DOSAGE FORM SECTION A. GENERAL INFORMATION

Dr Alan Winston. Imperial College Healthcare NHS Trust London. 7-8 October 2010, Queen Elizabeth II Conference Centre, London.

HIV associated CNS disease in the era of HAART

HIV in the Brain MANAGING COMORBIDITIES IN PATIENTS WITH HIV

HIV medications HIV medication and schedule plan

The use of antiretroviral agents during pregnancy in Canada and compliance with North-American guidelines

WOMEN'S INTERAGENCY HIV STUDY METABOLIC STUDY: MS01 SPECIMEN COLLECTION FORM

REIMBURSEMENT STATUS OF HIV MEDICATIONS IN ONTARIO

Distribution and Effectiveness of Antiretrovirals in the Central Nervous System

HIV DISEASE! Neurobehavioral! Neuromedical. Igor Grant, MD, FRCP(C) Director HIV Neurobehavioral Research Program University of California, San Diego

British HIV Association Guidelines for the Management of Hepatitis Viruses in Adults Infected with HIV 2013 Appendix 2

Drug Treatment Program Update

When to Start ART. Reduction in HIV transmission. ? Reduction in HIV-associated inflammation and associated complications» i.e. CV disease, neuro, etc

Simplifying HIV Treatment Now and in the Future

Second-Line Therapy NORTHWEST AIDS EDUCATION AND TRAINING CENTER

Medication Errors Focus on the HIV-Infected Patient

HIV THERAPY STRATEGIES FOR THIRD LINE. issues to consider when faced with few drug options

HIV basics. Katya Calvo Medical Director of Antimicrobial Stewardship

Fluconazole dimenhydrinate, diphenhydramine. Raltegravir or dolutegravir with antacids

MEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 03/07/18 SECTION: DRUGS LAST REVIEW DATE: 02/19/19 LAST CRITERIA REVISION DATE: ARCHIVE DATE:

Antiretroviral Therapy

PHARMACOKINETICS OF ANTIRETROVIRAL AND ANTI-HCV AGENTS


ANTIRETROVIRAL TREATMENTS (Part 1of

ART and Prevention: What do we know?

Nothing to disclose.

Comprehensive Guideline Summary

Criteria for Oral PrEP

HIV and AIDS An update

TB/HIV Co-Infection. Tuberculosis and HIV

Northwest AIDS Education and Training Center Educating health care professionals to provide quality HIV care

Continuing Education for Pharmacy Technicians

The Hospitalized HIV+ Patient

HIV and the Central Nervous System Impact of Drug Distribution Scott L. Letendre, MD. Professor of Medicine University of California, San Diego

Antiretroviral Pregnancy Registry

TB Intensive Tyler, Texas December 2-4, Tuberculosis and HIV Co-Infection. Lisa Y. Armitige, MD, PhD. December 4, 2008.

HIV/AIDS Update 2007

Human Immunodeficiency Virus (HIV) and Acquired Immune Deficiency Syndrome (AIDS) in the Long Term Care Setting Part 2: HIV Medications

Medscape's Antiretroviral Pocket Guide for the Treatment of HIV Infection

Nobel /03/28. HIV virus and infected CD4+ T cells

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 3 November 2010

Pharmacological considerations on the use of ARVs in pregnancy

HIV Pharmacology 101ish - 202ish: New HIV Clinicians Workshop

Selected Issues in HIV Clinical Trials

Pediatric Antiretroviral Resistance Challenges

Actualización y Futuro en VIH

Selected Issues in HIV Clinical Trials

PHCP 403 by L. K. Sarki

Pediatric HIV Infection and the Medical Management of Pregnant Women infected with HIV. Ernesto Parra, M.D., M.P.H.

ADAP Monitoring Provider Prescribing Patterns. Amanda Bowes, NASTAD Christine Rivera and Dr. Charles Gonzalez, NYS AIDS Institute

BHIVA ART Guideline 2014 update: SEARCH PROTOCOL: main databases search

HIV in in Women Women

U=U NHIVNA HIV, Fertility and Contraception in the era of

2 nd Line Treatment and Resistance. Dr Rohit Talwani & Dr Dave Riedel 12 th June 2012

Didactic Series. Update: 2012 HIV Treatment Guidelines. Daniel Lee, MD August 30, 2012

POST-EXPOSURE PROPHYLAXIS, PRE-EXPOSURE PROPHYLAXIS, & TREATMENT OF HIV

Terapia antirretroviral inicial y de rescate: Utilidad actual y futura de nuevos medicamentos

Antiretroviral Therapy During Pregnancy and Delivery: 2015 Update

HIV THERAPY STRATEGIES FOR FIRST LINE. issues to think about when going on therapy for the first time

HIV for the Non-ID Pharmacist

HIV Update. Divya Ahuja, MD Associate Professor of Medicine University of South Carolina School of Medicine

Didactic Series. Switching Regimens in the Setting of Virologic Suppression

NON-OCCUPATIONAL POST EXPOSURE PROPHYLAXIS IN HIV PREVENTION. Jason E. Vercher, PA-C, AAHIVM

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 9 May 2012

HIV Treatment: State of the Art 2013

HIV Update Objectives. Epidemiology. Epidemiology, Transmission and Natural History. Transmission Risk by Exposure. Transmission 9/29/2014

/AIDS HIV/ HIV Overview. Nelson L. Michael, MD, PhD Division of Retrovirology Walter Reed Army Institute of Research US Military HIV Research Program

The ART of Managing Drug-Drug Interactions in Patients with HIV

Treatment and Care: Product portfolio

Structured Treatment Interruption in HIV Positive Patients. Leah Jackson, BScPhm Pharmacy Resident HIV Rotation January 23, 2007

Update on Antiretroviral Treatment for HIV Infection 2008

Antiretroviral Drugs

Objectives. HIV Treatment in Recently In 1996 the introduction of protease inhibitors decreasing the death rate of those infected by 50%.

ALABAMA S ADAP FORMULARY OFFERS 117 MEDICATIONS

Appropriate Use & Safety Edits

ART: The New, The Old and The Ugly

Didactic Series. HIV Drug-Drug Interactions: OTC and non-prescription medications. Kirsten B. Balano, PharmD UCSF School of Pharmacy February 26, 2015

HIV Overview. Mary Marovich, MD, DTMH Division of Retrovirology Walter Reed Army Ins?tute of Research US Military HIV Research Program

Nuclear Receptors Mediated Induction of P-glycoprotein by Antiretroviral Drugs in Human Brain Microvessel Endothelial Cells

A Fatal Imbalance. Tropical diseases: 18 new drugs (incl. 8 for malaria) 1.3% 21 new drugs for neglected diseases. Tuberculosis: 3 new drugs

This graph displays the natural history of the HIV disease. During acute infection there is high levels of HIV RNA in plasma, and CD4 s counts

ART rapid scale up: the implications for patient care and retention. Dr Francesca Conradie Southern African HIV Clinicians Society

Supplemental Digital Content 1. Combination antiretroviral therapy regimens utilized in each study

Overview of HIV. LTC Paige Waterman

AUSTRALIAN HIV OBSERVATIONAL DATABASE ANNUAL REPORT

Antiretroviral Treatment (ART) of Adult HIV Infection*

ARVs in Development: Where do they fit?

ANTIRETROVIRAL THERAPY

Susan L. Koletar, MD

ARVs on an Empty Stomach: Food Interaction Studies in a resource Limited Setting

Transcription:

Industry Data Request Purpose: reported data will be used internally to populate patient forecasting models that are used for business planning. Business planning includes stock requirement forecasts, revenue forecasts and developing a general understanding of the market. NOTES: Table 1 (a) (c) (1) Some AHOD sites record fixed dose combination (fdc) drugs, such as Truvada, as their individual components (Emtricitabine and Tenofovir). (2) Some ARVs are masked with an X in order to reduce the total number of regimens and focus on the core components observed in AHOD. (3) Combinations with an X component are further described by whether the X s are from the NRTI class of drugs or Other (NNRTI, Fusion and Entry Inhibitors, Trial drug) or both NRTI and Other. (4) Combinations marked with a P indicate a Protease Inhibitor is used in the combination. (5) NRTI sparing is defined as a regimen without a NRTI component class drug. Table 7 & 8 (1) Patient are assumed to be on Atripla FDC if the individual drug components of Atripla (Truvada + Efavirenz or Tenofovir + Emtricitabine + Efavirenz) are reported for their regimen after 1/1/. (2) Combination antiretroviral therapy (cart) regimens are defined as 3 or more antiretroviral agents initiated after 1/1/1997 and have duration of usage more than 14 days. (3) A patient s regimen is classified by selecting the combination antiretroviral therapy regimen with the longest duration in each calendar year. To reduce the total number of possible cart combinations and to avoid direct head-to-head comparison of individual agents, the following groupings are used. Group Label NRTI NNRTI_1 NNRTI_2 PI_1 PI_2 PI_3 II OTHER Antiretroviral Therapy Agents abacavir, combivir, didanosine, lamivudine, stavudine, trizivir, zalcitabine, zidovudine, hydroxyurea, emtricitabine, truvada, kivexa, apricitabine, adefovir, tenofovir, enfuvirtide, IL-2 efavirenz, etravirine nevirapine, delavirdine atazanavir, darunavir kaletra, saquinavir amprenavir, indinavir, nelfinavir, ritonavir, tipranavir, fosamprenavir, lopinavir raltegravir maraviroc, trial drug

Table 1(a): Most frequent ARV combinations (3+ ARVs) in. 357 unique ART regimens; and a total of 2,066 regimens recorded among 1,719 patients on combination ART. Combination ARV Count Cumulative Count (%) Description of X NRTI Other NRTI + Other TRUVADA- NEV 150 7.3 TRUVADA- EFAV 143 14.2 KIVEXA- NEV 127 20.3 TRUVADA- ATAZ- RITON 97 25.0 ABC- NEV- X 92 29.5 92 KIVEXA- EFAV 75 33.1 ATAZ- RITON- TENOF- X 70 36.5 67 2 1 EFAV- TENOF- X 56 39.2 56 CBV- NEV 53 41.8 NEV- TENOF- X 49 44.1 49 KIVEXA- ATAZ- RITON 48 46.5 TRUVADA- KALETRA 44 48.6 KALETRA- TENOF- X 40 50.5 37 3 ABC- EFAV- X 33 52.1 33 CBV- EFAV 30 53.6 NEV- X 26 54.8 26 TRUVADA- RITON 26 56.1 KIVEXA- ATAZ 25 57.3 TRIZ 24 58.5 ABC- ATAZ- RITON- TENOF 23 59.6 ABC- ATAZ- RITON- X 23 60.7 23 ABC- KALETRA- X 17 61.5 17 EFAV- X 17 62.3 17 ABC- RITON- X 16 63.1 17 KIVEXA- KALETRA 15 63.8 RITON- DARUN- RALT- X 15 64.6 6 5 4 RITON- DARUN- TENOF- X 14 65.2 11 3 CBV- KALETRA 13 65.9 ABC- X 12 66.5 CBV- ATAZ 12 67.0 TRUVADA- ATAZ 12 67.6 KIVEXA- ATAZ- RITON- TENOF 11 68.2 ABC- ATAZ- X 10 68.6 ABC- KALETRA- TENOF 10 69.1 KIVEXA- RITON 10 69.6 RITON- DARUN- TENOF- RALT- X 10 70.1 7 3 NRTI SPARING 13 0.6 N/A

Table 1(b): Most frequent ARV combinations (3+ ARVs) in. 348 unique ART regimens; and a total of 1,986 regimens recorded among 1,707 patients on combination ART. Combination ARV Count Cumulative Count (%) Description of X NRTI Other NRTI + Other TRUVADA- EFAV 176 8.9 TRUVADA- NEV 164 17.1 KIVEXA- NEV 126 23.5 TRUVADA- ATAZ- RITON 101 28.5 KIVEXA- EFAV 73 32.2 ATAZ- RITON- TENOF- X 68 35.6 65 2 1 ABC- NEV- X 67 39.0 67 EFAV- TENOF- X 62 42.1 62 TRUVADA- KALETRA 55 44.9 CBV- NEV 45 47.2 KIVEXA- ATAZ- RITON 42 49.3 NEV- TENOF- X 42 51.4 42 KALETRA- TENOF- X 31 53.0 27 3 1 TRUVADA- RALT 29 54.4 RITON- DARUN- RALT- X 27 55.8 13 8 6 TRUVADA- RITON 25 57.0 KIVEXA- ATAZ 23 58.2 CBV- EFAV 22 59.3 ABC- ATAZ- RITON- X 21 60.4 21 TRIZ 21 61.4 ABC- EFAV- X 20 62.4 20 ABC- ATAZ- RITON- TENOF 18 63.3 KIVEXA- KALETRA 17 64.2 RITON- DARUN- TENOF- X 17 65.1 12 1 4 RITON- DARUN- TENOF- RALT- X 17 65.9 10 3 4 TRUVADA- ATAZ 16 66.7 NEV- X 14 67.4 14 TENOF- RALT- X 13 68.1 9 1 3 TRUVADA- RITON- DARUN- RALT- X 13 68.7 2 8 3 ABC- KALETRA- X 11 69.3 11 KIVEXA- ATAZ- RITON- TENOF 10 69.8 TRUVADA- RITON- DARUN 10 70.3 TRUVADA- RITON- DARUN- RALT 10 70.8 NRTI SPARING 26 1.3 N/A

Table 1(c): Most frequent ARV combinations (3+ ARVs) in. 335 unique ART regimens; and a total of 2,075 regimens recorded among 1,798 patients on combination ART. Combination ARV Count Cumulative Count (%) Description of X NRTI Other NRTI + Other TRUVADA- NEV 158 7.6 TRUVADA- EFAV 155 15.1 ATRIP 143 22.0 TRUVADA- ATAZ- RITON 106 27.1 KIVEXA- NEV 104 32.1 EFAV- TENOF- X 70 35.5 70 KIVEXA- EFAV 66 38.7 ABC- NEV- X 64 41.7 64 ATAZ- RITON- TENOF- X 60 44.6 59 1 TRUVADA- KALETRA 51 47.1 CBV- NEV 43 49.2 TRUVADA- RALT 43 51.2 NEV- TENOF- X 42 53.3 42 RITON- DARUN- RALT- X 41 55.2 11 21 9 KIVEXA- ATAZ- RITON 35 56.9 KALETRA- TENOF- X 29 58.3 25 3 1 TRUVADA- RITON 25 59.5 KIVEXA- ATAZ 23 60.6 RITON- DARUN- TENOF- RALT- X 23 61.7 13 2 8 ABC- ATAZ- RITON- X 21 62.7 21 ABC- EFAV- X 19 63.7 19 CBV- EFAV 19 64.6 TRIZ 18 65.4 TRUVADA- RITON- X 18 66.3 18 KIVEXA- KALETRA 17 67.1 RITON- DARUN- TENOF- X 16 67.9 10 1 5 TENOF- RALT- X 16 68.7 13 1 2 ABC- ATAZ- RITON- TENOF 15 69.4 TRUVADA- ATAZ 15 70.1 NEV- X 14 70.8 14 KALETRA- RALT- X 13 71.4 8 3 2 CBV- KALETRA 12 72.0 TRUVADA- RITON- DARUN- RALT- X 12 72.6 2 9 1 ABC- KALETRA- X 11 73.1 11 TRUVADA- RALT- X 11 73.6 10 1 TRUVADA- RITON- DARUN 11 74.2 ATAZ- RITON- RALT- X 10 74.7 8 2 KIVEXA- ATAZ- RITON- TENOF 10 75.1 TRUVADA- RITON- DARUN- RALT 10 75.6 NRTI SPARING 40 1.9 N/A

Table 2: The proportion of patients treated at one time with 2 or 3+ of the 3 rd agents: nevirapine, efavirenz, etravririne, indinavir, kaletra, atazanavir, darunavir, raltegravir. Year % Treated with 2 3 rd Agents % Treated with 3 or more 3 rd Agents 13.8 0.4 17.7 1.0 20.9 1.9 21.8 2.6 Table 3: The proportion of patients treated with more than 1 of the NRTI drugs: combivir, abacavir, kivexa, trivizivir, truvada, atripla. % Treated with Year more than 1 NRTI 0.7 1.0 1.1 1.2 Table 4 (a): cell count distribution of patients in follow-up over the period -. Median cell count per calendar year was catergorised into the groupings <200, 200-350, 350-500, >500 cells/µl. <200 88 (5) 81 (4) 86 (4) 89 (4) 200-349 249 (14) 230 (13) 227 (12) 220 (11) 350-499 380 (21) 402 (22) 425 (22) 435 (21) >500 942 (52) 983 (54) 1064 (56) 1127 (54) Missing 138 (8) 111 (6) 113 (6) 211 (10) Total 1797 1807 1915 2082 Table 4 (b): On or Off treatment* by cell count strata for patients in followup over the period -. <200 85/3 79/2 83/3 88/1 200-349 239/10 223/7 214/13 207/13 350-499 353/27 369/33 403/22 398/37 >500 880/62 920/63 999/65 1047/80 Missing 108/30 93/18 99/14 185/26 Total 1663/132 1684/123 1798/117 1925/157 *If a patient was On and Off treatment within the same year, then the treatment status with the larger duration of time was used.

Table 5 (a): cell count distribution of patients who enrolled in AHOD after 1/1/2005 and were recorded in follow-up over the period -. Median cell count per calendar year was catergorised into the groupings <200, 200-350, 350-500, >500 cells/µl. <200 13 (6) 10 (3) 30 (5) 41 (5) 200-349 41 (18) 54 (18) 95 (16) 112 (13) 350-499 51 (23) 82 (28) 158 (27) 215 (25) >500 107 (48) 136 (46) 273 (47) 434 (51) Missing 10 (5) 14 (5) 22 (4) 50 (6) Total 222 296 578 852 Table 5 (b): On or Off treatment by cell count strata for patients who enrolled in AHOD after 1/1/2005 and were recorded in follow-up over the period -. <200 12/1 9/1 28/2 40/1 200-349 36/5 51/3 86/9 102/10 350-499 39/12 63/19 141/17 183/32 >500 77/30 103/33 234/39 368/66 Missing 4/6 8/6 15/7 35/15 Total 168/54 234/62 504/74 728/124 *If a patient was On and Off treatment within the same year, then the treatment status with the larger duration of time was used. Table 6: The number and proportion of treatment naïve patients with a recent viral load measurement. The latest viral load from all measurement within 1/1/ 31/3/2011 was used to catergorise into groups 0-400, 400-10,000, >10,000 copies/ml. Viral Load Recent Visit (copies/ml) 0-50^ 24 15 50-400 16 10 400-10,000 49 31 >10,000 65 41 Missing 3 2 ^It is very likely most of these patients are actually on treatment, however due to reporting errors we have not yet received treatment data.

Table 7: The total number of patients that changed regimen from Atripla to another regimen and of those switches, the regimen they switched to. Regimens components have been reclassified as per the definitions present in the table on pg1. Atripla was made available on the PBS from 1/1/. Data based on all treatment changes from 1/1/-31/3/2011. Combination Number of Patients Total 30 NNRTI_2/NRTI 6 II/NRTI/PI_1/PI_3 4 NNRTI_1/NRTI 4 NRTI/PI_1/PI_3 3 II/NRTI 2 NRTI/NRTI/PI_1/PI_3 2 Other Combinations 9 Table 8: The total number of patients that changed regimen to Atripla from another regimen and of those switches, the regimen they switched from. Regimens components have been reclassified as per the definitions present in the table on pg1. Data based on all treatment changes from 1/1/-31/3/2011. Combination Number of Patients Total 173 NNRTI_1/NRTI/NRTI 70 NNRTI_1/NRTI 34 NNRTI_2/NRTI 20 NRTI/NRTI/PI_2 7 NRTI/PI_3 5 NNRTI_1/NRTI/NRTI/NRTI 4 NNRTI_2/NRTI/NRTI 4 NRTI/NRTI/PI_1/PI_3 4 NRTI/NRTI/PI_3 4 NRTI/PI_1/PI_3 3 NNRTI_1/NRTI/NRTI/PI_1/PI_3 2 NNRTI_1/NRTI/NRTI/PI_2 2 NNRTI_2/NRTI/PI_3/PI_3 2 NRTI 2 NRTI/NRTI/PI_2/PI_3 2 NRTI/NRTI/PI_3/PI_3 2 NRTI/PI_2 2 Other Combs 4

2024 © healthdocbox.com Privacy Policy | Terms of Service | Feedback